





PHARMACEUTICAL 2022


Cue Biopharma Inc.
Rank 219 of 466





PHARMACEUTICAL 2022

Cue Biopharma Inc.
Rank 219 of 466



The relative strengths and weaknesses of Cue Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cue Biopharma Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Cue Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 57% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	68,468
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,788
Liabilities, Non-Current	5,121
Other Assets	12,821
Other Compr. Net Income	-7.1
Other Expenses	495
Other Liabilities	0
Other Net Income	46
Other Revenues	14,941
Property and Equipment	2,112
Research and Development	41,347
Selling, General and Administrative Expense	17,307

Output Variable	Value in 1000 USD
Assets	83,401
Liabilities	17,909
Expenses	59,148
Revenues	14,941
Stockholders Equity	65,492
Net Income	-44,161
Comprehensive Net Income	-44,165
Economic Capital Ratio	135%